The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ Tregs
Open accessAbstract
One of the greatest barriers against harnessing the potential of CD4+ CD25+ Tregs as a cellular immunotherapy is their hypoproliferative phenotype. We have previously shown that the hypoproliferative response of Tregs to IL-2 is associated with defective downstream PI3K signaling. Here, we demonstrate that targeted deletion of the lipid phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome 10) regulates the peripheral homeostasis of Tregs in vivo and allows their expansion ex vivo in response to IL-2 alone. PTEN deficiency does not adversely affect either the thymic development or the function of Tregs, which retain their ability to suppress responder T cells in vitro and prevent colitis in vivo. Conversely, reexpression of PTEN in PTEN-deficient Tregs as well as in activated CD4+ T cells inhibits IL-2-dependent proliferation, confirming PTEN as a negative regulator of IL-2 receptor signaling. These data demonstrate that PTEN regulates the "anergic" response of Tregs to IL-2 in vitro and Treg homeostasis in vivo and indicate that inhibition of PTEN activity may facilitate the expansion of these cells for potential use in cellular immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PTEN: The down side of PI 3-kinase signalling
Leslie, N. R., & Downes, C. P. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00234-0 · Cited by 415
Cited by
Malek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
Sauer, S., Bruno, L., Hertweck, A., Finlay, D., Leleu, M., Spivakov, M., Knight, Z. A., Cobb, B. S., Cantrell, D., O'Connor, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800928105 · Cited by 865
Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
Malek, T. R., & Castro, I. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.004 · Cited by 851
Immunoregulatory functions of mTOR inhibition
Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2546 · Cited by 847
The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
Haxhinasto, S., Mathis, D., & Benoist, C. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071477 · Cited by 737
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
Klatzmann, D., & Abbas, A. K. (2015) · Nature Reviews Immunology · doi:10.1038/nri3823 · Cited by 636
GATA3 controls Foxp3+ regulatory T cell fate during inflammation in mice
Wohlfert, E. A., Grainger, J. R., Bouladoux, N., Konkel, J. E., Oldenhove, G., Ribeiro, C. H., Hall, J. A., Yagi, R., Naik, S., Bhairavabhotla, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57456 · Cited by 556
Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease
DuPage, M., & Bluestone, J. A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.18 · Cited by 513
Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability
Huynh, A., DuPage, M., Priyadharshini, B., Sage, P. T., Quiros, J., Borges, C. M., Townamchai, N., Gerriets, V. A., Rathmell, J. C., Sharpe, A. H., et al. (2015) · Nature Immunology · doi:10.1038/ni.3077 · Cited by 411
Zeiser, R., Leveson-Gower, D. B., Zambricki, E. A., Kambham, N., Beilhack, A., Loh, J., Hou, J.-Z., & Negrin, R. S. (2008) · Blood · doi:10.1182/blood-2007-06-094482 · Cited by 402
Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses
Shrestha, S., Yang, K., Guy, C., Vogel, P., Neale, G., & Chi, H. (2015) · Nature Immunology · doi:10.1038/ni.3076 · Cited by 364
Metabolic signaling in T cells
Shyer, J. A., Flavell, R. A., & Bailis, W. (2020) · Cell Research · doi:10.1038/s41422-020-0379-5 · Cited by 332
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function
Pompura, S. L., & Dominguez-Villar, M. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0817-349r · Cited by 288
Yin, Y., Cai, X., Chen, X., Liang, H., Zhang, Y., Li, J., Wang, Z., Chen, X., Zhang, W., Yokoyama, S., et al. (2014) · Cell Research · doi:10.1038/cr.2014.121 · Cited by 282
Yu, A., Zhu, L., Altman, N. H., & Malek, T. R. (2009) · Immunity · doi:10.1016/j.immuni.2008.11.014 · Cited by 263
mTOR signaling at the crossroads of environmental signals and T‐cell fate decisions
Huang, H., Long, L., Zhou, P., Chapman, N. M., & Chi, H. (2020) · Immunological Reviews · doi:10.1111/imr.12845 · Cited by 193
Acylglycerol Kinase Maintains Metabolic State and Immune Responses of CD8+ T Cells
Hu, Z., Qu, G., Yu, X., Jiang, H., Teng, X.-L., Ding, L., Hu, Q., Guo, X., Zhou, Y., Wang, F., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.016 · Cited by 87
Metadata
- Authors
- Walsh, P. T.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-08-17
- Volume
- 116
- Issue
- 9
- Pages
- 2521-31
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2116914415
- Cited by
- 164
- References
- 1
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.